An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF(TM) 1

Inhibition of the epithelial sodium channel (ENaC) represents an important, mutation-agnostic therapeutic approach to restore airway surface liquid in patients with cystic fibrosis (CF). A phase II trial of the ENaC inhibitor BI 1265162, inhaled via the Respimat® Soft Mist™ inhaler, in patients aged...

Descripción completa

Detalles Bibliográficos
Autores principales: Goss, Christopher H., Jain, Raksha, Seibold, Wolfgang, Picard, Anne-Caroline, Hsu, Ming-Chi, Gupta, Abhya, Fajac, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Study Protocols
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720689/
https://www.ncbi.nlm.nih.gov/pubmed/33313307
http://dx.doi.org/10.1183/23120541.00395-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720689/
https://www.ncbi.nlm.nih.gov/pubmed/33313307
http://dx.doi.org/10.1183/23120541.00395-2020

Ejemplares similares